Interstitial Lung Disease and Obstructive Sleep Apnea

February 7, 2026 updated by: Dan Liu

Study on the Clinical Characteristics of Interstitial Lung Disease and Obstructive Sleep Apnea

Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease.

All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
      • Tianjin, China, 300000
        • Recruiting
        • Tianjin Medical University General Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dan Liu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Interstitial lung disease and respiratory sleep apnoea

Description

Inclusion criteria:

  • over 18 years old and under 80 years old.
  • Clinical diagnosis of interstitial lung disease or obstructive respiratory sleep apnea syndrome.
  • Patient is conscious and capable of signing informed consent.
  • The patient may wear a polysomnograph.

Exclusion criteria:

  • malignant tumors.
  • severe heart failure.
  • uremia.
  • autoimmune diseases.
  • pulmonary embolism, and end-stage chronic obstructive pulmonary disease.
  • Patients with mental illnesscannot sign informed consent on their own.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ILD with OSA group
ILD patient diagnosed with OSA by PSG. Bronchoscopy was performed to obtain alveolar lavage fluid in ILD patients and lung tissue was obtained for ROSE and mNGS in appropriate patients
Diagnostic test: The relationship between imaging and ROSE and NGS
The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
Other Names:
  • Association between the severity of OSA and biological specimen examination
ILD without OSA
ILD patients excluded OSA through PSG. Bronchoscopy was performed to obtain alveolar lavage fluid in ILD patients and lung tissue was obtained for ROSE and mNGS in appropriate patients
Diagnostic test: The relationship between imaging and ROSE and NGS
The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
Other Names:
  • Association between the severity of OSA and biological specimen examination

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
imaging changes and ROSE and NGS in patients
Time Frame: 2Day
Relationship between imaging changes and ROSE and NGS in patients with interstitial lung disease
2Day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity and biological examination of OSA patients
Time Frame: 2Day
Classification of the severity of OSA and the relationship between positive results of biological or other tests
2Day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dan Liu

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2019

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

April 10, 2023

First Submitted That Met QC Criteria

April 20, 2023

First Posted (Actual)

May 1, 2023

Study Record Updates

Last Update Posted (Actual)

February 10, 2026

Last Update Submitted That Met QC Criteria

February 7, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dliu

Drug and device information, study documents

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ILD OSA

Clinical Trials on The relationship between imaging and ROSE and NGS

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe